18F Sodium Fluoride PET CT in patients with Acute Aortic Syndrome
Research type
Research Study
Full title
18F Sodium Fluoride PET CT in patients with Acute Aortic Syndrome
IRAS ID
239677
Contact name
David Newby
Contact email
Sponsor organisation
University of Edinburgh
Clinicaltrials.gov Identifier
AC18044, ACCORD Sponsor Number
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Acute aortic syndrome is a devastating clinical condition involving a tear in the largest blood vessel of the body - the aorta. Patients may require urgent surgery if the blood supply to limbs or organs is affected. Otherwise, usual treatment is with blood pressure lowering medication. However, despite these efforts, the weakened aorta is prone to expansion and the catastrophic consequence of rupture.
To date, there remains no way of predicting aortic expansion in acute aortic syndrome. Applying new technologies to imaging the aorta allows us to study specific disease processes. A biological tracer called 18F-Sodium Fluoride (18F-NaF) can be used with positron emission tomography (PET) scanning to visualise areas of tissue disease within the aorta. This tracer is safe and has been used in numerous human studies.
As part of our research, we will include PET imaging to the established surveillance pathway of patients with acute aortic syndrome (during their routine 30-day and 12-month CT scan). We will take this opportunity to perform a clinical assessment and blood tests on volunteers.
Finally, we will report:
(i) the distribution of 18F-NaF binding to the aorta;
(ii) associations between 18F-NaF and changes in the shape of the aorta;
(iii) associations between 18F-NaF and acute aortic syndrome-related complications.REC name
East of Scotland Research Ethics Service REC 2
REC reference
18/ES/0070
Date of REC Opinion
9 Jul 2018
REC opinion
Further Information Favourable Opinion